TAVI is more expensive than a traditional AVR, doubles your risk of stroke and major vascular events, and outcome benefits are far from established. There is also a financial scandal reminiscent of the Manny Rivers affair, argues this analysis in the BMJ. Cheers to Mark L for sending this in.
TAVI – not worth the money?
Be the first to start the conversation!